GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
GRAIL, Inc.NASDAQ: GRAL
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 9.9% from a year ago
Total equity stood at $2.54B at the end of Q2 FY2026, up 9.9% from a year earlier and up 1.7% from the prior quarter. Over 3 fiscal years it compounded at -17.8% a year.
Context
- Total equity amounted to 89.4% of total assets at the end of Q2 FY2026, up 3.8 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +9.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 2.58B USD
- Year-over-year change
- +3.0%
- 4-year CAGR
- -27.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.58B | +3.0% |
| FY2024 | 2024-12-31 | 2.5B | -31.3% |
| FY2023 | 2023-12-31 | 3.65B | -21.5% |
| FY2022 | 2022-12-31 | 4.65B | -50.7% |
| FY2021 | 2021-12-31 | 9.43B | — |
Total Equity vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's Jun 2026 total equity of $2.54B is the highest of the 10 companies compared; the peer median is $461.42M.
- Its year-over-year change of +9.9% is the 5th highest of 10, against a peer median of +4.8%.
- Total equity amounts to 89.4% of total assets for GRAL, versus a peer median of 68.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.54B | +9.9% | -17.8% | 89.4% | |
| Jun 2026 | $1.82B | +46.2% | +34.4% | 68.5% | |
| Mar 2026 | $1.04B | -7.0% | -4.5% | 90.3% | |
| Jun 2026 | $785.73M | -8.0% | -5.7% | 58.1% | |
BLLNBillionToOne, Inc. | Jun 2026 | $536.81M | +217.3% | — | 73.6% |
| Mar 2026 | $461.42M | +4.8% | +5.7% | 84.2% | |
| Mar 2026 | $337.4M | -52.1% | -25.4% | 50.1% | |
| Mar 2026 | $254.77M | +22.9% | +6.2% | 78.3% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $244.22M | -11.9% | +6.7% | 50.7% |
| Sep 2026 | -$275.9M | +22.2% | — | 14.6% | |
| Peer median (excluding GRAL) | $461.42M | +4.8% | +5.7% | 68.5% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 221.16M | 241.6M | 97.29M | 214.23M | 249.73M |
| Short-term Investments | 0 | 0 | 0 | 549.24M | 654.7M |
| Net Receivables | 6.88M | 18.62M | 22.35M | 24.64M | 18.3M |
| Inventory | 0 | 19.76M | 21.7M | 18.63M | 16.02M |
| Other Current Assets | 6.89M | 0 | 0 | 0 | 15.11M |
| Total Current Assets | 242.73M | 295.63M | 156.07M | 819.86M | 953.85M |
| Property, Plant & Equipment (Net) | 216.37M | 198.72M | 169.38M | 135.43M | 103.88M |
| Goodwill | 6.2B | 1.5B | 888.94M | 0 | 0 |
| Intangible Assets | 3.07B | 2.94B | 2.69B | 2.02B | 1.85B |
| Long-term Investments | 0 | 4.53M | 4.23M | 0 | 6.97M |
| Tax Assets | 0 | 664.12M | 643.11M | 0 | 0 |
| Other Non-current Assets | 7.1M | 6.14M | 7.98M | 11.12M | 6.75M |
| Total Non-current Assets | 9.5B | 5.31B | 4.4B | 2.16B | 1.97B |
| Total Assets | 9.74B | 5.6B | 4.56B | 2.98B | 2.92B |
| Account Payables | 17.65M | 17.48M | 19.67M | 4.84M | 2.08M |
| Short-term Debt | 0 | 13.34M | 14.81M | 0 | 11.72M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 1.6M | 0 |
| Other Current Liabilities | 4.51M | 65.96M | 87.64M | 22.69M | 65.87M |
| Total Current Liabilities | 97.89M | 134.94M | 163.61M | 76.93M | 79.67M |
| Long-term Debt | 0 | 0 | 0 | 0 | 43.15M |
| Deferred Tax Liabilities | 0 | 735.19M | 676.03M | 345.86M | 218.58M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 112.76M | 3.13M | 1.5M | 2.24M | (40.4M) |
| Total Non-current Liabilities | 209.51M | 821M | 747.13M | 402.98M | 264.48M |
| Total Liabilities | 307.4M | 955.94M | 910.74M | 479.9M | 344.15M |
| Common Stock | 10.34B | 10.96B | 11.42B | 34K | 40K |
| Retained Earnings | (911.54M) | (6.31B) | (7.78B) | (9.8B) | (10.21B) |
| Accumulated OCI | 315K | 894K | 1.07M | 1.45M | 2.66M |
| Other Stockholders Equity | 1 | 0 | 1 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 9.43B | 4.65B | 3.65B | 2.5B | 2.58B |
| Total Debt | 110.56M | 96.01M | 84.41M | 68.14M | 98.01M |
| Net Debt | (110.6M) | (145.59M) | (12.88M) | (146.09M) | (151.72M) |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.